Evidence map›Paper›PMID 22566748›Full record

ArticleVascular health and risk management2012

Treatment patterns and risk factor control in patients with and without metabolic syndrome in cardiac rehabilitation.

Anselm Gitt, Christina Jannowitz, Marthin Karoff, Barbara Karmann, Martin Horack, Heinz Völler

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in Vascular health and risk management, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01985048 (Cardiometabolic Risk in the Setting of Cardiac Rehabilitation), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01985048 unknown statusnot on this mapstarted 2013, after this paper: background citation

Cardiometabolic Risk in the Setting of Cardiac Rehabilitation

TypeobservationalSponsorHealth Diagnostic Laboratory, Inc.Ran2013 to 2015Enrolled500ConditionsCoronary Artery Disease
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Effect of cardiac rehabilitation on metabolic syndrome and its components: A systematic review and meta-analysis.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Anselm GittInstitut für Herzinfarktforschung an der Universität Heidelberg, Ludwigshafen, Germany.
Christina Jannowitz
Marthin Karoff
Barbara Karmann
Martin Horack
Heinz Völler
Heidelberg University · DEMSD (Germany) · DEWitten/Herdecke University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimMetabolic syndrome (MetS) is a clustering of factors that are associated with increased cardiovascular risk. We aimed to investigate the proportion of patients with MetS in patients undergoing cardiac rehabilitation (CR), and to describe differences between patients with MetS compared to those without MetS with regard to (1) patient characteristics including demographics, risk factors, and comorbidities, (2) risk factor management including drug treatment, and (3) control status of risk factors at entry to CR and discharge from CR.

methodsPost-hoc analysis of data from 27,904 inpatients (Transparency Registry to Objectify Guideline-Oriented Risk Factor Management registry) that underwent a CR period of about 3 weeks were analyzed descriptively in total and compared by their MetS status.

resultsIn the total cohort, mean age was 64.3 years, (71.7% male), with no major differences between groups. Patients had been referred after a ST elevation of myocardial infarction event in 41.1% of cases, non-ST elevation of myocardial infarction in 21.8%, or angina pectoris in 16.7%. They had received a percutaneous coronary intervention in 55.1% and bypass surgery (coronary artery bypass graft) in 39.5%. Patients with MetS (n = 15,819) compared to those without MetS (n = 12,085) were less frequently males, and in terms of cardiac interventions, more often received coronary artery bypass surgery. Overall, statin use increased from 79.9% at entry to 95.0% at discharge (MetS: 79.7% to 95.2%). Patients with MetS compared to those without MetS received angiotensin converting enzyme inhibitors, angiotensin receptor blockers, oral antidiabetics, and insulin at entry and discharge more frequently, and less frequently clopidogrel and aspirin/clopidogrel combinations. Mean blood pressure was within the normal range at discharge, and did not differ substantially between groups (124/73 versus 120/72 mmHg). Overall, between entry and discharge, levels of total cholesterol, low density lipoprotein cholesterol, and triglycerides were substantially lowered, in particular in MetS patients. Thus, control rates of lipid parameters improved substantially, with the exception of high density lipoprotein cholesterol. Low density lipoprotein cholesterol rates <100 mg/dL increased from 38.7% at entry to 73.8% at discharge (MetS: from 39.4% to 74.6%) and triglycerides control rates (<150 mg/dL) from 58.1% to 70.4% (MetS: 43.7% to 62.2%). Physical fitness on exercise testing improved substantially in both groups.

conclusionPatients with and without MetS benefited substantially from the participation in CR, as their lipid profile, blood pressure, and physical fitness improved. Treatment effects were similar in the two groups.

Indexed as

AgedAngioplasty, Balloon, CoronaryBlood GlucoseBlood PressureCardiovascular AgentsChi-Square DistributionComorbidityCoronary Artery BypassDrug Therapy, CombinationDrug UtilizationFemaleGermanyGuideline AdherenceHeart DiseasesHumansInpatientsBlood GlucoseCardiovascular AgentsLipidscardiac rehabilitationcontrol ratesdiabetesdyslipidemialipidsmetabolismregistryrisk factor

Identifiers

PMID22566748
PMCPMC3346265
OpenAlexW1657478987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.